Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Merel van Nuland"'
Autor:
Merel van Nuland, Anne-Fleur H. Lobbezoo, Ewoudt M.W. van de Garde, Maikel Herbrink, Inger van Heijl, Tim Bognàr, Jeroen P.A. Houwen, Marloes Dekens, Demi Wannet, Toine Egberts, Paul D. van der Linden
Publikováno v:
Exploratory Research in Clinical and Social Pharmacy, Vol 15, Iss , Pp 100464- (2024)
Background: The advent of Large Language Models (LLMs) such as ChatGPT introduces opportunities within the medical field. Nonetheless, use of LLM poses a risk when healthcare practitioners and patients present clinical questions to these programs wit
Externí odkaz:
https://doaj.org/article/0dec1526e8624f9b9b3ec871c3215346
Autor:
Merel van Nuland, Madelon Butterhoff, Karin Verwijmeren, Florine Berger, Vera M. Hogervorst, Annemarieke de Jonghe, Paul D van der Linden
Publikováno v:
BMC Geriatrics, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Older patients are vulnerable to experiencing drug related problems (DRPs), which may result in emergency department (ED) visits. However, it is not standard practice to conduct medications reviews during ED visit. The aim of this
Externí odkaz:
https://doaj.org/article/feefcca851744f75875bd2aeaee9f8a1
Publikováno v:
Clinical and Translational Science. 16:258-268
Microdosing is a strategy to obtain knowledge of human pharmacokinetics prior to Phase I clinical trials. The most frequently used method to extrapolate microdose (≤100 μg) pharmacokinetics to therapeutic doses is based on linear extrapolation fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daaeaa6311168b819386fed37275eedf
https://doi.org/10.1111/cts.13446
https://doi.org/10.1111/cts.13446
Autor:
Marit A. C. Vermunt, Merel van Nuland, Lisa T. van der Heijden, Hilde Rosing, Jos. H. Beijnen, Andries M. Bergman
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:785-793
Purpose Recently, docetaxel treatment of metastatic prostate cancer patients shifted towards the hormone-sensitive stage of the disease. There are contradictive reports on differences in toxicity of docetaxel in metastatic hormone-sensitive prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fc3388e3c1dbfd0c859372c79029629
https://doi.org/10.1007/s00280-022-04433-3
https://doi.org/10.1007/s00280-022-04433-3
Autor:
Merel van Nuland, Madelon Butterhoff, Karin Verwijmeren, Florine Berger, Vera M. Hogervorst, Annemarieke de Jonghe, Paul van der Linden
Background Older patients are at risk of drug related problems (DRPs), potentially leading to emergency department (ED) visits. Identifying DRPs with medication reviews is typically evaluated in restrictive clinical studies and not in a ‘real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d7c41183ce6a0662284374204f02db2
https://doi.org/10.21203/rs.3.rs-2230828/v1
https://doi.org/10.21203/rs.3.rs-2230828/v1
Autor:
Renske M.T. ten Ham, Alwin D. R. Huitema, Rick A. Vreman, Andre M. Bergman, Hilde Rosing, Merel van Nuland, Anke M. Hövels, Laurens G. de Graaf, Jos H. Beijnen
Publikováno v:
Value in Health. 24:121-128
Objectives Abiraterone acetate is registered for the treatment of metastatic castration-sensitive and resistant prostate cancer (mCRPC). Treatment outcome is associated with plasma trough concentrations (Cmin) of abiraterone. Patients with a plasma C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b8b6af34c83b1b893d65f35a013a8fb
https://doi.org/10.1016/j.jval.2020.04.1838
https://doi.org/10.1016/j.jval.2020.04.1838
Autor:
Merel van Nuland, Andries M. Bergman, Vincent O. Dezentjé, Alwin D. R. Huitema, Neeltje Steeghs, Stefanie L. Groenland, Jeantine M de Feijter, Jos H. Beijnen, Hilde Rosing
Publikováno v:
European Journal of Cancer, 130, 32. Elsevier Ltd
AIM: Abiraterone acetate is approved for the treatment of metastatic prostate cancer. At the currently used fixed dose of 1000 mg once daily in modified fasting state, 40% of patients do not reach the efficacy threshold of a minimum plasma concentrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c548b45b4c1406b84161e72341410b
https://doi.org/10.1016/j.ejca.2020.02.012
https://doi.org/10.1016/j.ejca.2020.02.012
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 23, Iss 818, p 818 (2022)
International Journal of Molecular Sciences, Vol 23, Iss 818, p 818 (2022)
The prevalence of obesity has increased dramatically in the Western population. Obesity is known to influence not only the proportion of adipose tissue but also physiological processes that could alter drug pharmacokinetics. Yet, there are no specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0947a739a579f980c745bcd985a9ca55
http://europepmc.org/articles/PMC8775906
http://europepmc.org/articles/PMC8775906
Autor:
Marit A C, Vermunt, Merel, van Nuland, Lisa T, van der Heijden, Hilde, Rosing, Jos H, Beijnen, Andries M, Bergman
Publikováno v:
Cancer chemotherapy and pharmacology. 89(6)
Recently, docetaxel treatment of metastatic prostate cancer patients shifted towards the hormone-sensitive stage of the disease. There are contradictive reports on differences in toxicity of docetaxel in metastatic hormone-sensitive prostate cancer (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e29743ca14f1d0f1e9cd6c500ac524f1
https://pubmed.ncbi.nlm.nih.gov/35467095
https://pubmed.ncbi.nlm.nih.gov/35467095
Autor:
Bart A. W. Jacobs, M.A.C. Bruin, Andre M. Bergman, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, Merel van Nuland
Publikováno v:
Journal of Clinical Oncology. 39:5035-5035
5035 Background: Abiraterone acetate is an effective metastatic castration resistant prostate cancer (mCRPC) treatment, however, there is a high variability in response. It inhibits CYP17, thereby preventing the production of androgens. Abiraterone t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ea1b166ec23d72c27c7cd48be24252f
https://doi.org/10.1200/jco.2021.39.15_suppl.5035
https://doi.org/10.1200/jco.2021.39.15_suppl.5035